All Types of Coffee are Protective against Chronic Liver Disease, Study Shows
By Science News Staff / Source
In a study involving almost 500,000 adults from the United Kingdom, a team of scientists from the University of Southampton and the University of Edinburgh Centre for Inflammation Research found that drinking coffee that is caffeinated (ground or instant) or decaffeinate was associated with a reduced risk of developing and dying from chronic liver disease compared to not drinking coffee, with the benefit peaking at three to four cups per day.
Drinking any type of coffee is
associated with a reduced risk of developing chronic liver disease and related
liver conditions.
Chronic liver disease is a major
health problem worldwide, particularly in low to middle-income countries with
high disease burden and limited treatment availability.
The commonest aetiologies of chronic liver disease are alcohol-related liver disease, chronic hepatitis B and C infection, and non-alcoholic fatty liver disease. These conditions involve destruction and regeneration of liver parenchyma leading to liver fibrosis and then cirrhosis.
Coffee is a popular beverage in most
societies. It comprises hundreds of chemical compounds, some of which are
thought to have in vivo properties, including
caffeine, chlorogenic acid, kahweol and cafestol.
Coffee consumption has been linked
with lower rates of chronic liver disease, but little is known about the effects
of different coffee types.
“The aim of our study was to
investigate associations of coffee consumption, including the effects of
different coffee types — and, thus, composition — with chronic liver disease
outcomes in a large prospective cohort,” said lead author Dr. Oliver Kennedy
from the Faculty of Medicine at the University of Southampton and his
colleagues.
The researchers analyzed UK Biobank
data on 495,585 participants with known coffee consumption, who were followed
over a median of 10.7 years to monitor who developed chronic liver disease and
related liver conditions.
Of all participants included in the
study, 78% (384,818) consumed ground or instant caffeinated or decaffeinated
coffee, while 22% (109,767) did not drink any type of coffee.
During the study period, there were
3,600 cases of chronic liver disease, including 301 deaths. Additionally, there
were 5,439 cases of chronic liver disease or steatosis, and 184 cases of
hepatocellular carcinoma.
Compared to non-coffee drinkers,
coffee-drinkers had a 21% reduced risk of chronic liver disease, a 20% reduced
risk of chronic or fatty liver disease, and a 49% reduced risk of death from
chronic liver disease.
The maximum benefit was seen in the
group who drank ground coffee, which contains high levels of kahweol and
cafestol.
Instant coffee, which has low levels
of these compounds, was also associated with a reduced the risk of chronic
liver disease.
While the reduction in risk was
smaller than that associated with ground coffee, the finding may suggest that
other ingredients, or potentially a combination of ingredients, may be
beneficial.
“Coffee is widely accessible and the
benefits we see from our study may mean it could offer a potential preventative
treatment for chronic liver disease,” Dr. Kennedy said.
“This would be especially valuable
in countries with lower income and worse access to healthcare and where the
burden of chronic liver disease is highest.”
The results appear in the journal BMC Public Health.
_____
O.J. Kennedy et al.
2021. All coffee types decrease the risk of adverse clinical outcomes in
chronic liver disease: a UK Biobank study. BMC Public Health 21,
970; doi: 10.1186/s12889-021-10991-7